Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis

AME Lung Cancer Collaborative Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: This study aims to determine the association of EGFR/KRAS mutation status with histological subtypes of lung adenocarcinoma (LAC) based on the IASLC/ATS/ERS classification. Methods: Pubmed and Cochrane databases were searched from January 2011 to June 2018 for studies that included patients with LAC who underwent surgical resection were classified according to the new IASLC/ATS/ERS classification. EGFR/KRAS status assessment was requireded. The primary outcome was determined by the odds ratio (OR) of the incidence of mutation status of certain of each histological subtype. The reference group consisted of EGFR/KRAS mutation negative patients. Results: Twenty-seven eligible studies involving 9022 patients with mutation gene detection were included for analysis. Among them, 6717 (74.5%) patients were from the Asian region and, 2305 (25.5%) patients were from Non-Asian regions. The most prevalent subtype was acinar (34.7%), followed by papillary (22.9%), lepidic (18.9%), solid (13.6%), micropapillary (6.3%), and invasive mucinous adenocarcinoma (3.5%). EGFR mutations were more common in patients with resected lepidic predominant adenocarcinoma (OR,1.76; 95%CI, 1.38–2.24;p < 0.01) and were rarely found in solid predominant adenocarcinoma (OR,0.28; 95%CI, 0.23–0.34;p < 0.01) or IMA (OR,0.10; 95%CI, 0.06–0.14;p < 0.01). Conversely, KRAS mutations were characterized by IMA (OR,7.01; 95%CI, 5.11–9.62;p < 0.01), and were less frequently identified in lepidic (OR,0.58; 95%CI, 0.45–0.75;p < 0.01) and acinar (OR,0.65; 95%CI, 0.55–0.78;p < 0.01) predominant subtypes. Further analyses were performed in Asian and Non-Asian groups and the results were consistent. Conclusions: The current study confirms that the IASLC/ATS/ERS classification is associated with driver gene alterations in resected LAC.

Original languageEnglish (US)
JournalEuropean Journal of Surgical Oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Odds Ratio
Mutation
Adenocarcinoma
Mucinous Adenocarcinoma
Adenocarcinoma of lung
PubMed
Genes
Databases
Incidence

Keywords

  • EGFR
  • IASLC/ATS/ERS classification
  • KRAS
  • Lung adenocarcinoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

@article{87bd8a262df645e3b274177cec0efcb6,
title = "Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis",
abstract = "Objectives: This study aims to determine the association of EGFR/KRAS mutation status with histological subtypes of lung adenocarcinoma (LAC) based on the IASLC/ATS/ERS classification. Methods: Pubmed and Cochrane databases were searched from January 2011 to June 2018 for studies that included patients with LAC who underwent surgical resection were classified according to the new IASLC/ATS/ERS classification. EGFR/KRAS status assessment was requireded. The primary outcome was determined by the odds ratio (OR) of the incidence of mutation status of certain of each histological subtype. The reference group consisted of EGFR/KRAS mutation negative patients. Results: Twenty-seven eligible studies involving 9022 patients with mutation gene detection were included for analysis. Among them, 6717 (74.5{\%}) patients were from the Asian region and, 2305 (25.5{\%}) patients were from Non-Asian regions. The most prevalent subtype was acinar (34.7{\%}), followed by papillary (22.9{\%}), lepidic (18.9{\%}), solid (13.6{\%}), micropapillary (6.3{\%}), and invasive mucinous adenocarcinoma (3.5{\%}). EGFR mutations were more common in patients with resected lepidic predominant adenocarcinoma (OR,1.76; 95{\%}CI, 1.38–2.24;p < 0.01) and were rarely found in solid predominant adenocarcinoma (OR,0.28; 95{\%}CI, 0.23–0.34;p < 0.01) or IMA (OR,0.10; 95{\%}CI, 0.06–0.14;p < 0.01). Conversely, KRAS mutations were characterized by IMA (OR,7.01; 95{\%}CI, 5.11–9.62;p < 0.01), and were less frequently identified in lepidic (OR,0.58; 95{\%}CI, 0.45–0.75;p < 0.01) and acinar (OR,0.65; 95{\%}CI, 0.55–0.78;p < 0.01) predominant subtypes. Further analyses were performed in Asian and Non-Asian groups and the results were consistent. Conclusions: The current study confirms that the IASLC/ATS/ERS classification is associated with driver gene alterations in resected LAC.",
keywords = "EGFR, IASLC/ATS/ERS classification, KRAS, Lung adenocarcinoma",
author = "{AME Lung Cancer Collaborative Group} and Long Jiang and Mari Mino-Kenudson and Anja Roden and Rafael Rosell and Molina, {Miguel {\'A}ngel} and Flores, {Raja M.} and Pilz, {Lothar R.} and Alessandro Brunelli and Federico Venuta and Jianxing He",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ejso.2019.02.006",
language = "English (US)",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status

T2 - A systematic literature review and pooled-data analysis

AU - AME Lung Cancer Collaborative Group

AU - Jiang, Long

AU - Mino-Kenudson, Mari

AU - Roden, Anja

AU - Rosell, Rafael

AU - Molina, Miguel Ángel

AU - Flores, Raja M.

AU - Pilz, Lothar R.

AU - Brunelli, Alessandro

AU - Venuta, Federico

AU - He, Jianxing

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: This study aims to determine the association of EGFR/KRAS mutation status with histological subtypes of lung adenocarcinoma (LAC) based on the IASLC/ATS/ERS classification. Methods: Pubmed and Cochrane databases were searched from January 2011 to June 2018 for studies that included patients with LAC who underwent surgical resection were classified according to the new IASLC/ATS/ERS classification. EGFR/KRAS status assessment was requireded. The primary outcome was determined by the odds ratio (OR) of the incidence of mutation status of certain of each histological subtype. The reference group consisted of EGFR/KRAS mutation negative patients. Results: Twenty-seven eligible studies involving 9022 patients with mutation gene detection were included for analysis. Among them, 6717 (74.5%) patients were from the Asian region and, 2305 (25.5%) patients were from Non-Asian regions. The most prevalent subtype was acinar (34.7%), followed by papillary (22.9%), lepidic (18.9%), solid (13.6%), micropapillary (6.3%), and invasive mucinous adenocarcinoma (3.5%). EGFR mutations were more common in patients with resected lepidic predominant adenocarcinoma (OR,1.76; 95%CI, 1.38–2.24;p < 0.01) and were rarely found in solid predominant adenocarcinoma (OR,0.28; 95%CI, 0.23–0.34;p < 0.01) or IMA (OR,0.10; 95%CI, 0.06–0.14;p < 0.01). Conversely, KRAS mutations were characterized by IMA (OR,7.01; 95%CI, 5.11–9.62;p < 0.01), and were less frequently identified in lepidic (OR,0.58; 95%CI, 0.45–0.75;p < 0.01) and acinar (OR,0.65; 95%CI, 0.55–0.78;p < 0.01) predominant subtypes. Further analyses were performed in Asian and Non-Asian groups and the results were consistent. Conclusions: The current study confirms that the IASLC/ATS/ERS classification is associated with driver gene alterations in resected LAC.

AB - Objectives: This study aims to determine the association of EGFR/KRAS mutation status with histological subtypes of lung adenocarcinoma (LAC) based on the IASLC/ATS/ERS classification. Methods: Pubmed and Cochrane databases were searched from January 2011 to June 2018 for studies that included patients with LAC who underwent surgical resection were classified according to the new IASLC/ATS/ERS classification. EGFR/KRAS status assessment was requireded. The primary outcome was determined by the odds ratio (OR) of the incidence of mutation status of certain of each histological subtype. The reference group consisted of EGFR/KRAS mutation negative patients. Results: Twenty-seven eligible studies involving 9022 patients with mutation gene detection were included for analysis. Among them, 6717 (74.5%) patients were from the Asian region and, 2305 (25.5%) patients were from Non-Asian regions. The most prevalent subtype was acinar (34.7%), followed by papillary (22.9%), lepidic (18.9%), solid (13.6%), micropapillary (6.3%), and invasive mucinous adenocarcinoma (3.5%). EGFR mutations were more common in patients with resected lepidic predominant adenocarcinoma (OR,1.76; 95%CI, 1.38–2.24;p < 0.01) and were rarely found in solid predominant adenocarcinoma (OR,0.28; 95%CI, 0.23–0.34;p < 0.01) or IMA (OR,0.10; 95%CI, 0.06–0.14;p < 0.01). Conversely, KRAS mutations were characterized by IMA (OR,7.01; 95%CI, 5.11–9.62;p < 0.01), and were less frequently identified in lepidic (OR,0.58; 95%CI, 0.45–0.75;p < 0.01) and acinar (OR,0.65; 95%CI, 0.55–0.78;p < 0.01) predominant subtypes. Further analyses were performed in Asian and Non-Asian groups and the results were consistent. Conclusions: The current study confirms that the IASLC/ATS/ERS classification is associated with driver gene alterations in resected LAC.

KW - EGFR

KW - IASLC/ATS/ERS classification

KW - KRAS

KW - Lung adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85062220887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062220887&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2019.02.006

DO - 10.1016/j.ejso.2019.02.006

M3 - Article

C2 - 30833014

AN - SCOPUS:85062220887

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

ER -